Giredestrant (Wilserdly) + everolimus (Afinitor) is now approved for HR+, HER2- metastatic breast cancer with an ESR1 mutation, based on the evERA trial. Komen is proud to have supported research that helped advance this treatment. Learn more: bit.ly/3VpfiUN
Susan G. Komen®
@SusanGKomen
Susan G. Komen® is driven by our vision to create a world where no one dies from breast cancer.
bit.ly/3dN7twd
bit.ly/3dN7twd
3.7K Following 104K Followers 22K Posts
Latest posts 5
Biomarkers can provide important clues about a tumor and help doctors identify the best treatment options for their patients.
Learn more about how biomarkers can open doors to more personalized care. komen.org/blog/know-more…
#CancerBiomarker #BiomarkerTesting #CBAD26
Learn more about how biomarkers can open doors to more personalized care. komen.org/blog/know-more…
#CancerBiomarker #BiomarkerTesting #CBAD26